High-Administered Activity In-111 Octreotide Therapy with Concomitant Radiosensitizing 5FU Chemotherapy for Treatment of Neuroendocrine Tumors: Preliminary Experience-Reference-Cited by-同舟云学术

High-Administered Activity In-111 Octreotide Therapy with Concomitant Radiosensitizing 5FU Chemotherapy for Treatment of Neuroendocrine Tumors: Preliminary Experience

Published:2009-10 Issue:5 Volume:24 Page:527-533
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Kong Grace¹,Johnston Val¹,Ramdave Shakher¹,Lau Eddie¹,Rischin Danny²,Hicks Rodney J.¹

Affiliation:

1. From the Center for Molecular Imaging, Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia.

2. From the Division of Hematology and Medical Oncology, Peter MacCallum Cancer Center, East Melbourne, Victoria, Australia.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

http://www.liebertpub.com/doi/pdf/10.1089/cbr.2009.0644

Reference24 articles.

1. Somatostatin Receptor: Scintigraphy and Radionuclide Therapy

2. Treatment With the Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate: Toxicity, Efficacy, and Survival

3. Peptide Receptor Radionuclide Therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours

4. Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy

Cited by 43 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination Strategies and Targeted Radionuclide Therapies;Seminars in Nuclear Medicine;2024-07

2. Efficacy and safety of temozolomide-based regimens in advanced pancreatic neuroendocrine tumors: a systematic review and meta-analysis;BMC Cancer;2024-02-12

3. Peptide receptor chemoradionuclide therapy for neuroendocrine neoplasms: A systematic review;Journal of Neuroendocrinology;2023-11-21

4. PRRT for higher-grade neuroendocrine neoplasms: What is still acceptable?;Current Opinion in Pharmacology;2022-12

5. Neuroendocrine Tumor Theranostics: An Update and Emerging Applications in Clinical Practice;American Journal of Roentgenology;2021-08